Search

Your search keyword '"Post, Marco C."' showing total 64 results
Start Over Author "Post, Marco C." Database OAIster
64 results on '"Post, Marco C."'

2. Complications of Balloon Pulmonary Angioplasty: A Comprehensive Analysis Based on the Latest ESC Consensus Statement

Author

Circulatory Health, Team Medisch, van Leusden, Fe J., Staal, Diederik P., van Thor, Mitch C.J., Rensing, Benno J.M.W., van Kuijk, Jan Peter, Mulder, Berend M., van den Heuvel, Daniël A.F., Boerman, Sanne, Boomars, Karin A., Peper, Joyce, Mager, Johannes J., Post, Marco C., Circulatory Health, Team Medisch, van Leusden, Fe J., Staal, Diederik P., van Thor, Mitch C.J., Rensing, Benno J.M.W., van Kuijk, Jan Peter, Mulder, Berend M., van den Heuvel, Daniël A.F., Boerman, Sanne, Boomars, Karin A., Peper, Joyce, Mager, Johannes J., and Post, Marco C.

Published
2024

3. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study

Author

Team Medisch, Circulatory Health, Malgie, Jishnu, Wilde, Mariëlle I, Clephas, Pascal R D, Emans, Mireille E, Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J, van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C Jan Willem, Saraber, Colette, Beeres, Saskia L M A, van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A, Klip, IJsbrand T, Manintveld, Olivier C, van der Boon, Robert M A, van Ofwegen, Clara E E, Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C M, Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E C, Bouhuijzen, Lex J, Post, Marco C, Kuijper, Aaf F M, Wu, Ka Wai, van Beek, Eugène A, Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J M, Tio, René A, Langerveld, Jorina, van Dalen, Bas M, van Eck, J W Martijn, Handoko, M Louis, Hermans, Walter R M, Koornstra-Wortel, Hetty J J, Szymanski, Mariusz K, Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C M, Asselbergs, Folkert W, van der Meer, Peter, Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A, Brugts, Jasper J, Team Medisch, Circulatory Health, Malgie, Jishnu, Wilde, Mariëlle I, Clephas, Pascal R D, Emans, Mireille E, Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J, van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C Jan Willem, Saraber, Colette, Beeres, Saskia L M A, van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A, Klip, IJsbrand T, Manintveld, Olivier C, van der Boon, Robert M A, van Ofwegen, Clara E E, Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C M, Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E C, Bouhuijzen, Lex J, Post, Marco C, Kuijper, Aaf F M, Wu, Ka Wai, van Beek, Eugène A, Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J M, Tio, René A, Langerveld, Jorina, van Dalen, Bas M, van Eck, J W Martijn, Handoko, M Louis, Hermans, Walter R M, Koornstra-Wortel, Hetty J J, Szymanski, Mariusz K, Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C M, Asselbergs, Folkert W, van der Meer, Peter, Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A, and Brugts, Jasper J

Published
2024

4. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure:Design and rationale of the BioMEMS study

Author

Allach, Youssra, de Jong, Mylene Barry-Loncq, Clephas, Pascal R. D., van Gent, Marco W. F., Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K., van Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E. M., Asselbergs, Folkert W., van Kimmenade, Roland R. J., Manintveld, Olivier C., van Mieghem, Nicolas M. D. A., Beeres, Saskia L. M. A., Rienstra, Michiel, Post, Marco C., van Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C. M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D. J., van Ramshorst, Jan, Kirchhof, Charles J. H. J., Feenema-Aardema, Margriet W., da Fonseca, Carlos A., van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J. W. Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A., Brugts, Jasper J., Allach, Youssra, de Jong, Mylene Barry-Loncq, Clephas, Pascal R. D., van Gent, Marco W. F., Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K., van Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E. M., Asselbergs, Folkert W., van Kimmenade, Roland R. J., Manintveld, Olivier C., van Mieghem, Nicolas M. D. A., Beeres, Saskia L. M. A., Rienstra, Michiel, Post, Marco C., van Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C. M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D. J., van Ramshorst, Jan, Kirchhof, Charles J. H. J., Feenema-Aardema, Margriet W., da Fonseca, Carlos A., van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J. W. Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF-related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early-stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods: The BioMEMS study, a substudy of the MONITOR-HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR-HF trial were collected at baseline, 3-, 6-, and 12-month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS-HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death. Conclusion: Since the prognostic value of single baseline measurements of biomarkers like N-terminal pro-B-type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.

Published
2024

5. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients:First data from the TITRATE-HF study

Author

Malgie, Jishnu, Wilde, Mariëlle I., Clephas, Pascal R.D., Emans, Mireille E., Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J., van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C. Jan Willem, Saraber, Colette, Beeres, Saskia L.M.A., van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A., Klip, IJsbrand T., Manintveld, Olivier C., van der Boon, Robert M.A., van Ofwegen, Clara E.E., Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C.M., Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E.C., Bouhuijzen, Lex J., Post, Marco C., Kuijper, Aaf F.M., Wu, Ka wai, van Beek, Eugène A., Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J.M., Tio, René A., Langerveld, Jorina, van Dalen, Bas M., van Eck, J. W.Martijn, Handoko, M. Louis, Hermans, Walter R.M., Koornstra-Wortel, Hetty J.J., Szymanski, Mariusz K., Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C.M., Asselbergs, Folkert W., van der Meer, Peter, Brunner-La Rocca, Hans Peter, de Boer, Rudolf A., Brugts, Jasper J., Malgie, Jishnu, Wilde, Mariëlle I., Clephas, Pascal R.D., Emans, Mireille E., Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J., van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C. Jan Willem, Saraber, Colette, Beeres, Saskia L.M.A., van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A., Klip, IJsbrand T., Manintveld, Olivier C., van der Boon, Robert M.A., van Ofwegen, Clara E.E., Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C.M., Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E.C., Bouhuijzen, Lex J., Post, Marco C., Kuijper, Aaf F.M., Wu, Ka wai, van Beek, Eugène A., Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J.M., Tio, René A., Langerveld, Jorina, van Dalen, Bas M., van Eck, J. W.Martijn, Handoko, M. Louis, Hermans, Walter R.M., Koornstra-Wortel, Hetty J.J., Szymanski, Mariusz K., Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C.M., Asselbergs, Folkert W., van der Meer, Peter, Brunner-La Rocca, Hans Peter, de Boer, Rudolf A., and Brugts, Jasper J.

Abstract

Aims: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real-world implementation lags behind. Closely following the 2021 ESC HF guidelines and 2023 focused update, the TITRATE-HF study started to prospectively investigate the use, sequencing, and titration of guideline-directed medical therapy (GDMT) in HF patients, including the identification of implementation barriers. Methods and results: TITRATE-HF is an ongoing long-term HF registry conducted in the Netherlands. Overall, 4288 patients from 48 hospitals were included. Among these patients, 1732 presented with de novo, 2240 with chronic, and 316 with worsening HF. The median age was 71 years (interquartile range [IQR] 63–78), 29% were female, and median ejection fraction was 35% (IQR 25–40). In total, 44% of chronic and worsening HFrEF patients were prescribed quadruple therapy. However, only 1% of HFrEF patients achieved target dose for all drug classes. In addition, quadruple therapy was more often prescribed to patients treated in a dedicated HF outpatient clinic as compared to a general cardiology outpatient clinic. In each GDMT drug class, 19% to 36% of non-use in HFrEF patients was related to side-effects, intolerances, or contraindications. In the de novo HF cohort, 49% of patients already used one or more GDMT drug classes for other indications than HF. Conclusion: This first analysis of the TITRATE-HF study reports relatively high use of GDMT in a contemporary HF cohort, while still showing room for improvement regarding quadruple therapy. Importantly, the use and dose of GDMT were suboptimal, with the reasons often remaining unclear. This underscores the urgency for further optimization of GDMT and implementation strategies within HF management.

Published
2024

6. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study

Author

Team Medisch, Circulatory Health, Allach, Youssra, Barry-Loncq de Jong, Mylene, Clephas, Pascal R D, van Gent, Marco W F, Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K, van Halm, Vokko P, Handoko, M Louis, Kok, Wouter E M, Asselbergs, Folkert W, van Kimmenade, Roland R J, Manintveld, Olivier C, van Mieghem, Nicolas M D A, Beeres, Saskia L M A, Rienstra, Michiel, Post, Marco C, van Heerebeek, Loek, Borleffs, C Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C M, Spee, Ruud F, Emans, Mireille E, Smilde, Tom D J, van Ramshorst, Jan, Kirchhof, Charles J H J, Feenema-Aardema, Margriet W, da Fonseca, Carlos A, van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J W Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A, Brugts, Jasper J, Team Medisch, Circulatory Health, Allach, Youssra, Barry-Loncq de Jong, Mylene, Clephas, Pascal R D, van Gent, Marco W F, Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K, van Halm, Vokko P, Handoko, M Louis, Kok, Wouter E M, Asselbergs, Folkert W, van Kimmenade, Roland R J, Manintveld, Olivier C, van Mieghem, Nicolas M D A, Beeres, Saskia L M A, Rienstra, Michiel, Post, Marco C, van Heerebeek, Loek, Borleffs, C Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C M, Spee, Ruud F, Emans, Mireille E, Smilde, Tom D J, van Ramshorst, Jan, Kirchhof, Charles J H J, Feenema-Aardema, Margriet W, da Fonseca, Carlos A, van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J W Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A, and Brugts, Jasper J

Published
2024

7. Complications of Balloon Pulmonary Angioplasty:A Comprehensive Analysis Based on the Latest ESC Consensus Statement

Author

van Leusden, Fe J., Staal, Diederik P., van Thor, Mitch C.J., Rensing, Benno J.M.W., van Kuijk, Jan Peter, Mulder, Berend M., van den Heuvel, Daniël A.F., Boerman, Sanne, Boomars, Karin A., Peper, Joyce, Mager, Johannes J., Post, Marco C., van Leusden, Fe J., Staal, Diederik P., van Thor, Mitch C.J., Rensing, Benno J.M.W., van Kuijk, Jan Peter, Mulder, Berend M., van den Heuvel, Daniël A.F., Boerman, Sanne, Boomars, Karin A., Peper, Joyce, Mager, Johannes J., and Post, Marco C.

Abstract

Background/Objectives: The literature reports high complication rates in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who undergo balloon pulmonary angioplasty (BPA), especially in patients with poor pulmonary hemodynamics. Here, we describe the complications of BPA based on the new definitions. Methods: All patients with CTEPH who completed BPA treatment before 15 September 2023 were selected from the CTEPH database. Peri-procedural complications were collected and classified according to the 2023 consensus paper on BPA treatment. Complications were analyzed in subgroups of patients with pulmonary vascular resistance (PVR), ≤ or >6.6 WU, and mean pulmonary artery pressure (mPAP), ≤ or >45 mmHg, at first BPA. Results: In this analysis, 87 patients (63% women; mean age 61.1 ± 14.0 years; 62% on dual PH targeted medical therapy) underwent 426 (mean 4.9 ± 1.6 per patient) BPAs. Only non-severe complications occurred in 14% of BPA treatments and in 47% of the patients; 31% patients had a thoracic complication. The thoracic complications were mild (71%) or moderate (29%). Patients with a PVR > 6.6 WU (n = 8) underwent more BPA treatments (6.6 ± 1.5 versus 4.6 ± 1.5, p = 0.002), had more complications (88% versus 41% of patients, p = 0.020), and had more thoracic complications (17% vs. 7% of BPAs, p = 0.013) than patients with PVR ≤ 6.6 WU. Patients with mPAP > 45 mmHg (n = 13) also had more BPA treatments (6.5 ± 1.7 versus 4.6 ± 1.4, p < 0.001), more complications (77% versus 44% of patients, p = 0.027) and more thoracic complications (14% versus 8% of BPAs, p = 0.039) than patients with mPAP ≤ 45 mmHg. Conclusions: Complications occurred in 14% of BPAs and were mostly mild. Patients with severe pulmonary hemodynamics suffered more (thoracic) complications.

Published
2024

8. Male-Female Differences in Acute Type B Aortic Dissection

Author

Meccanici, Frederike, Thijssen, Carlijn G.E., Heijmen, Robin H., Geuzebroek, Guillaume S.C., Ter Woorst, Joost F., Gökalp, Arjen L., de Bruin, Jorg L., Gratama, Daantje N., Bekkers, Jos A., van Kimmenade, Roland R.J., Poyck, Paul, Peels, Kathinka, Post, Marco C., Mokhles, Mostafa M., Takkenberg, Johanna J.M., Roos-Hesselink, Jolien W., Verhagen, Hence J.M., Meccanici, Frederike, Thijssen, Carlijn G.E., Heijmen, Robin H., Geuzebroek, Guillaume S.C., Ter Woorst, Joost F., Gökalp, Arjen L., de Bruin, Jorg L., Gratama, Daantje N., Bekkers, Jos A., van Kimmenade, Roland R.J., Poyck, Paul, Peels, Kathinka, Post, Marco C., Mokhles, Mostafa M., Takkenberg, Johanna J.M., Roos-Hesselink, Jolien W., and Verhagen, Hence J.M.

Abstract

BACKGROUND: Acute type B aortic dissection is a cardiovascular emergency with considerable mortality and morbidity risk. Male-female differences have been observed in cardiovascular disease; however, literature on type B aortic dissection is scarce. METHODS AND RESULTS: A retrospective cohort study was conducted including all consecutive patients with acute type B aortic dissection between 2007 and 2017 in 4 tertiary hospitals using patient files and questionnaires for late morbidity. In total, 384 patients were included with a follow-up of 6.1 (range, 0.02-14.8) years, of which 41% (n=156) were female. Women presented at an older age than men (67 [interquartile range (IQR), 57-73] versus 62 [IQR, 52-71]; P=0.015). Prior abdominal aortic aneurysm (6% versus 15%; P=0.009), distally extending dissections (71 versus 85%; P=0.001), and clinical malperfusion (18% versus 32%; P=0.002) were less frequently observed in women. Absolute maximal descending aortic diameters were smaller in women (36 [IQR: 33-40] mm versus 39 [IQR, 36-43] mm; P<0.001), while indexed for body surface area diameters were larger in women (20 [IQR, 18-23] mm/m2 versus 19 [IQR, 17-21] mm/m2). No male-female differences were found in treatment choice; however, indications for invasive treatment were different (P<0.001). Early mortality rate was 9.6% in women and 11.8% in men (P=0.60). The 5-year survival was 83% (95% CI, 77-89) for women and 84% (95% CI, 79-89) for men (P=0.90). No male-female differences were observed in late (re)interventions. CONCLUSIONS: No male-female differences were found in management, early or late death, and morbidity in patients presenting with acute type B aortic dissection, despite distinct clinical profiles at presentation. More details on the impact of age and type of intervention are warranted in future studies.

Published
2024

9. Long-Term Health-Related Quality of Life following Acute Type A Aortic Dissection with a Focus on Male-Female Differences: A Cross Sectional Study

Author

R&D Onderzoek, Cardiologie Arts-onderzoekers, Team Medisch, Circulatory Health, Meccanici, Frederike, Thijssen, Carlijn G E, Gökalp, Arjen L, Bom, Annemijn W, Geuzebroek, Guillaume S C, Ter Woorst, Joost F, van Kimmenade, Roland R J, Post, Marco C, Takkenberg, Johanna J M, Roos-Hesselink, Jolien W, R&D Onderzoek, Cardiologie Arts-onderzoekers, Team Medisch, Circulatory Health, Meccanici, Frederike, Thijssen, Carlijn G E, Gökalp, Arjen L, Bom, Annemijn W, Geuzebroek, Guillaume S C, Ter Woorst, Joost F, van Kimmenade, Roland R J, Post, Marco C, Takkenberg, Johanna J M, and Roos-Hesselink, Jolien W

Published
2024

10. Male-Female Differences in Acute Type B Aortic Dissection

Author

Team Medisch, Circulatory Health, CTC, Meccanici, Frederike, Thijssen, Carlijn G E, Heijmen, Robin H, Geuzebroek, Guillaume S C, Ter Woorst, Joost F, Gökalp, Arjen L, de Bruin, Jorg L, Gratama, Daantje N, Bekkers, Jos A, van Kimmenade, Roland R J, Poyck, Paul, Peels, Kathinka, Post, Marco C, Mokhles, Mostafa M, Takkenberg, Johanna J M, Roos-Hesselink, Jolien W, Verhagen, Hence J M, Team Medisch, Circulatory Health, CTC, Meccanici, Frederike, Thijssen, Carlijn G E, Heijmen, Robin H, Geuzebroek, Guillaume S C, Ter Woorst, Joost F, Gökalp, Arjen L, de Bruin, Jorg L, Gratama, Daantje N, Bekkers, Jos A, van Kimmenade, Roland R J, Poyck, Paul, Peels, Kathinka, Post, Marco C, Mokhles, Mostafa M, Takkenberg, Johanna J M, Roos-Hesselink, Jolien W, and Verhagen, Hence J M

Published
2024

11. Long-Term Health-Related Quality of Life following Acute Type A Aortic Dissection with a Focus on Male–Female Differences:A Cross Sectional Study

Author

Meccanici, Frederike, Thijssen, Carlijn G.E., Gökalp, Arjen L., Bom, Annemijn W., Geuzebroek, Guillaume S.C., ter Woorst, Joost F., van Kimmenade, Roland R.J., Post, Marco C., Takkenberg, Johanna J.M., Roos-Hesselink, Jolien W., Meccanici, Frederike, Thijssen, Carlijn G.E., Gökalp, Arjen L., Bom, Annemijn W., Geuzebroek, Guillaume S.C., ter Woorst, Joost F., van Kimmenade, Roland R.J., Post, Marco C., Takkenberg, Johanna J.M., and Roos-Hesselink, Jolien W.

Abstract

Objectives: Acute type A aortic dissection (ATAAD) is a life-threatening cardiovascular emergency, of which the long-term impact on health-related quality of life (HRQoL) and male–female-specific insights remain inadequately clarified. Methods: Consecutive adult ATAAD patients who underwent surgery were retrospectively included between 2007 and 2017 in four referral centers in the Netherlands, and baseline data were collected. The 36-Item Short-Form (SF-36) Health Survey was sent to all survivors between 2019 and 2021 and compared to validated SF-36 scores of the Dutch general population stratified by age group and sex. Results: In total, 324/555 surviving patients returned the SF-36 questionnaire (response rate 58%), of which 40.0% were female; the median follow-up was 6.5 years (range: 1.7–13.9, IQR: 4.0–9.4) after surgery for ATAAD. In comparison to the general population, ATAAD patients scored significantly lower on 6/8 SF-36 subdomains and higher on bodily pain. Differences in HRQoL domains compared to the sex-matched data were largely comparable between sexes, apart from bodily pain. In the age-matched subgroups impaired HRQoL was most pronounced in younger patients aged 41–60 (5/8 impaired domains). Female ATAAD patients scored significantly worse on 5/8 SF-36 subdomains and the physical component summary (PCS) scores than male patients. Age at ATAAD, female sex, hypertension, COPD, and prior thoracic aortic aneurysm were associated with worse PCS scores. Conclusions: Long-term HRQoL was impaired in both male and female ATAAD patients when compared to the general population. Further studies on the nature of this impairment and on interventions to improve HRQoL after ATAAD are clearly warranted, with special attention to females and younger patients.

Published
2024

12. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis

Author

Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G M, van de Garde, Ewoudt M W, Veltkamp, Marcel, Akdim, Fatima, Post, Marco C, Grutters, Jan C, Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G M, van de Garde, Ewoudt M W, Veltkamp, Marcel, Akdim, Fatima, Post, Marco C, and Grutters, Jan C

Abstract

Background: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and methotrexate has gained attention as steroid sparing agent although the supporting evidence is poor. This study compared prednisone monotherapy, methotrexate monotherapy or a combination of both, in the reduction of myocardial Fluorine-18 fluorodeoxyglucose (FDG) uptake and clinical stabilization of CS patients. Methods and results: In this retrospective cohort study, 61 newly diagnosed and treatment naïve CS patients commenced treatment with prednisone (N = 21), methotrexate (N = 30) or prednisone and methotrexate (N = 10) between January 2010 and December 2017. Primary outcome was metabolic response on FDG PET/CT and secondary outcomes were treatment patterns, major adverse cardiovascular events, left ventricular ejection fraction, biomarkers and side effects. At a median treatment duration of 6.2 [5.7-7.2] months, 71.4% of patients were FDG PET/CT responders, and the overall myocardial maximum standardized uptake value decreased from 6.9 [5.0-10.1] to 3.4 [2.1-4.7] (P < 0.001), with no significant differences between treatment groups. During 24 months of follow-up, 7 patients (33.3%; prednisone), 6 patients (20.0%; methotrexate) and 1 patient (10.0%; combination group) experienced at least one major adverse cardiovascular event (P = 0.292). Left ventricular ejection fraction was preserved in all treatment groups. Conclusions: Significant suppression of cardiac FDG uptake occurred in CS patients after 6 months of prednisone, methotrexate or combination therapy. There were no significant differences in clinical outcomes during follow-up. These results warrant further investigation of methotrexate treatment in CS patients.

Published
2023

13. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G M, van de Garde, Ewoudt M W, Veltkamp, Marcel, Akdim, Fatima, Post, Marco C, Grutters, Jan C, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G M, van de Garde, Ewoudt M W, Veltkamp, Marcel, Akdim, Fatima, Post, Marco C, and Grutters, Jan C

Published
2023

14. Long Term Health Related Quality of Life After Acute Type B Aortic Dissection:a Cross Sectional Survey Study

Author

Meccanici, Frederike, Thijssen, Carlijn G.E., Gökalp, Arjen L., Bom, Annemijn W., de Bruin, Jorg L., Bekkers, Jos A., van Kimmenade, Roland R.J., Geuzebroek, Guillaume S.C., Poyck, Paul, Woorst, Joost J.ter, Peels, Kathinka, Sjatskig, Jelena, Heijmen, Robin H., Post, Marco C., Mokhles, Mostafa M., Verhagen, Hence J.M., Takkenberg, Johanna J.M., Roos-Hesselink, Jolien W., Meccanici, Frederike, Thijssen, Carlijn G.E., Gökalp, Arjen L., Bom, Annemijn W., de Bruin, Jorg L., Bekkers, Jos A., van Kimmenade, Roland R.J., Geuzebroek, Guillaume S.C., Poyck, Paul, Woorst, Joost J.ter, Peels, Kathinka, Sjatskig, Jelena, Heijmen, Robin H., Post, Marco C., Mokhles, Mostafa M., Verhagen, Hence J.M., Takkenberg, Johanna J.M., and Roos-Hesselink, Jolien W.

Abstract

Objective: Acute type B aortic dissection (ATBD) is a rare yet serious cardiovascular event that potentially has an impact on health related quality of life (HRQoL). However, long term follow up data on this topic are scarce. This study aimed to review the long term HRQoL among patients treated for ATBD. Methods: In this multicentre, cross sectional survey study, consecutive treated patients with ATBD between 2007 and 2017 in four referral centres in the Netherlands were retrospectively included and baseline data were collected. Between 2019 and 2021 the 36 Item Short Form Survey (SF-36) was sent to all surviving patients (n = 263) and was compared with validated SF-36 scores in the Dutch general population stratified by age and sex. Results: In total, 144 of 263 surviving patients completed the SF-36 (response rate 55%). Median (IQR) age was 68 (61, 76) years at completion of the questionnaire, and 40% (n = 58) were female. Initial treatment was medical in 55% (n = 79), endovascular in 41% (n = 59), and surgical in 4% (n = 6) of ATBD patients. Median follow up time was 6.1 (range 1.7–13.9; IQR 4.0, 9.0) years. Compared with the general population, patients scored significantly worse on six of eight SF-36 subdomains, particularly physical domains. Apart from bodily pain, there were no substantial differences in HRQoL between male and female ATBD patients. Compared with sex matched normative data, females scored significantly worse on five of eight subdomains, whereas males scored significantly lower on six subdomains. Younger patients aged 41–60 years seemed more severely impaired in HRQoL compared with the age matched general population. Treatment strategy did not influence HRQoL outcomes. Follow up time was associated with better Physical and Mental Component Summary scores. Conclusion:Long term HRQoL was impaired in ATBD patients compared with the Dutch general population, especially

Published
2023

15. Clinical Characteristics and Outcomes of Patients With Cutibacterium acnes Endocarditis

Author

Heinen, Floris J., Arregle, Florent, van den Brink, Floris S., Ajmone Marsan, Nina, Bernts, Lucas, Houthuizen, Patrick, Kamp, Otto, Roescher, Nienke, Timmermans, Naomi, Verkaik, Nelianne, Roos-Hesselink, Jolien, Post, Marco C., Habib, Gilbert, Tanis, Wilco, Heinen, Floris J., Arregle, Florent, van den Brink, Floris S., Ajmone Marsan, Nina, Bernts, Lucas, Houthuizen, Patrick, Kamp, Otto, Roescher, Nienke, Timmermans, Naomi, Verkaik, Nelianne, Roos-Hesselink, Jolien, Post, Marco C., Habib, Gilbert, and Tanis, Wilco

Abstract

Importance: It is suggested that patients with Cutibacterium acnes endocarditis often present without fever or abnormal inflammatory markers. However, no study has yet confirmed this statement. Objective: To assess the clinical characteristics and outcomes of patients with C acnes endocarditis. Design, Setting, and Participants: A case series of 105 patients presenting to 7 hospitals in the Netherlands and France (4 university hospitals and 3 teaching hospitals) with definite endocarditis according to the modified Duke criteria between January 1, 2010, and December 31, 2020, was performed. Clinical characteristics and outcomes were retrieved from medical records. Cases were identified by blood or valve and prosthesis cultures positive for C acnes, retrieved from the medical microbiology databases. Infected pacemaker or internal cardioverter defibrillator lead cases were excluded. Statistical analysis was performed in November 2022. Main Outcomes and Measures: Main outcomes included symptoms at presentation, presence of prosthetic valve endocarditis, laboratory test results at presentation, time to positive results of blood cultures, 30-day and 1-year mortality rates, type of treatment (conservative or surgical), and endocarditis relapse rates. Results: A total of 105 patients (mean [SD] age, 61.1 [13.9] years; 96 men [91.4%]; 93 patients [88.6%] with prosthetic valve endocarditis) were identified and included. Seventy patients (66.7%) did not experience fever prior to hospital admission, nor was it present at hospitalization. The median C-reactive protein level was 3.6 mg/dL (IQR, 1.2-7.5 mg/dL), and the median leukocyte count was 10.0 × 103/µL (IQR, 8.2-12.2 × 103/µL). The median time to positive blood culture results was 7 days (IQR, 6-9 days). Surgery or reoperation was indicated for 88 patients and performed for 80 patients. Not performing the indicated surgical procedure was associated with high mortality rates. Seventeen patients were treated conservatively

Published
2023

16. Sexual function is impaired in women and men with pulmonary hypertension

Author

Hendriks, Paul M., Staal, Diederik P., Pastoor, Hester, Kolpa, Corine I.A., van den Bosch, Annemien E., Post, Marco C., Boomars, Karin A., Hendriks, Paul M., Staal, Diederik P., Pastoor, Hester, Kolpa, Corine I.A., van den Bosch, Annemien E., Post, Marco C., and Boomars, Karin A.

Abstract

Background: Sexual health related quality of life (SHRQoL) is an important pillar of health related quality of life (HRQoL). The aim of this study was to investigate sexual functioning in men and women with pulmonary hypertension (PH). Methods and results: In this cross-sectional study, a total of 78 patients were included, 49 were diagnosed with pulmonary arterial hypertension and 29 with chronic thromboembolic pulmonary hypertension (median age 53 [IQR: 46–67 years], 66.7% female). All patients completed SHRQoL questionnaires; for women: ASEX, FSFI, and FSDS and for men: ASEX and IIEF. A PH-specific SHRQoL questionnaire was created based on 4 semi-structured interviews to investigate PH-specific barriers in sexuality. More than half of the patients experienced symptoms during sexual activity, mainly dyspnea (52.6%) and palpitations (32.1%). Sexual dysfunction was present, according to the FSFI-questionnaire, in 63.0% of women. All of the men experienced at least mild dysfunction in one of the domains of the IIEF and erectile dysfunction was present in 48.0%. Sexual dysfunction occurred more often in both men and women with PH than in the general population. PAH-specific medication was not associated with sexual dysfunction, nor was subcutaneous or intravenous pump therapy (OR 1.14, 95%-CI: 0.75–1.73). Diuretics were associated with sexual dysfunction in women (OR 4.01, 95%-CI: 1.04–15.41). Of all patients committed in a relationship, 69.0% would like to discuss sexuality with their healthcare provider. Conclusion: This study showed a high prevalence of sexual dysfunction in men and women with PH. It is important for healthcare providers to discuss sexuality with patients. Graphical abstract: [Figure not available: see fulltext.].

Published
2023

17. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis

Author

Informatisering, Longziekten, Cardiologie, Team Medisch, Circulatory Health, Infection & Immunity, Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G.M., van de Garde, Ewoudt M.W., Veltkamp, Marcel, Akdim, Fatima, Post, Marco C., Grutters, Jan C., Informatisering, Longziekten, Cardiologie, Team Medisch, Circulatory Health, Infection & Immunity, Vis, Roeland, Mathijssen, Harold, Keijsers, Ruth G.M., van de Garde, Ewoudt M.W., Veltkamp, Marcel, Akdim, Fatima, Post, Marco C., and Grutters, Jan C.

Published
2023

18. Common genetic variants improve risk stratification after the atrial switch operation for transposition of the great arteries

Author

Cardiologie, Team Medisch, Circulatory Health, Woudstra, Odilia I., Skoric-Milosavljevic, Doris, Mulder, Barbara J.M., Meijboom, Folkert J., Post, Marco C., Jongbloed, Monique R.M., van Dijk, Arie P.J., van Melle, Joost P., Konings, Thelma C., Postma, Alex V., Bezzina, Connie R., Bouma, Berto J., Tanck, Michael W.T., Cardiologie, Team Medisch, Circulatory Health, Woudstra, Odilia I., Skoric-Milosavljevic, Doris, Mulder, Barbara J.M., Meijboom, Folkert J., Post, Marco C., Jongbloed, Monique R.M., van Dijk, Arie P.J., van Melle, Joost P., Konings, Thelma C., Postma, Alex V., Bezzina, Connie R., Bouma, Berto J., and Tanck, Michael W.T.

Published
2023

19. Cardiovascular magnetic resonance-derived left ventricular intraventricular pressure gradients among patients with precapillary pulmonary hypertension

Author

Circulatory Health, Researchgr. Cardiovasculaire Radiologie, Vos, Jacqueline L., Leiner, Tim, van Dijk, Arie P.J., Pedrizzetti, Gianni, Alenezi, Fawaz, Rodwell, Laura, van der Wegen, Constantijn T.P.M., Post, Marco C., Driessen, Mieke M.P., Nijveldt, Robin, Circulatory Health, Researchgr. Cardiovasculaire Radiologie, Vos, Jacqueline L., Leiner, Tim, van Dijk, Arie P.J., Pedrizzetti, Gianni, Alenezi, Fawaz, Rodwell, Laura, van der Wegen, Constantijn T.P.M., Post, Marco C., Driessen, Mieke M.P., and Nijveldt, Robin

Published
2023

20. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure

Author

Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., and Shah, Sanjiv J.

Abstract

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome - a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status - was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P=0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P=0.038). Patients with larger right atrial volum

Published
2022

21. The evolution of survival of pulmonary arterial hypertension over 15 years

Author

Hendriks, Paul M., Staal, Diederik P., van de Groep, Liza D., van den Toorn, Leon M., Chandoesing, Prewesh P., Kauling, Robert M., Mager, Hans Jurgen, van den Bosch, Annemien E., Post, Marco C., Boomars, Karin A., Hendriks, Paul M., Staal, Diederik P., van de Groep, Liza D., van den Toorn, Leon M., Chandoesing, Prewesh P., Kauling, Robert M., Mager, Hans Jurgen, van den Bosch, Annemien E., Post, Marco C., and Boomars, Karin A.

Abstract

The prognosis of pulmonary arterial hypertension (PAH) remains dismal. Over the years, multiple therapeutic advances have been introduced. This study evaluates the evolution of PAH survival over the past 15 years. We included 293 consecutive adult patients diagnosed with PAH between 2005 and 2019 (median age: 61.8 years, 70.3% female). Patients were divided into three cohorts based on the time of diagnosis: 2005–2009, 2010–2014, and 2015–2019 (2005–2009: n = 56; 2010–2014: n = 111; 2015–2019: n = 126). Transplant-free survival was measured from the date of right heart catheterization until patients reached the composite endpoint of lung transplant or death. Multivariable cox-pulmonary hypertension regression was used to study the effect of the time of diagnosis. The final cox model was fitted in both younger and older patients to evaluate the difference between these groups. During a median follow-up time of 4.1 (interquartile range: 2.2–7.3) years, 9 patients underwent lung transplantation and 151 patients died. The median overall transplant-free survival was 6.2 (5.5–8.0) years. Patients older than 56 years at baseline who were diagnosed in 2005–2009 showed better survival compared to patients diagnosed in 2010–2014 and 2015–2019 with an adjusted hazard ratio of, respectively, 2.12 (1.11–4.03) and 2.83 (1.41–5.69). Patients younger than 56 years showed neither an improved nor deteriorated survival over time. In conclusion, survival in patients with PAH did not improve over time, despite more available therapeutic options. This might be partly due to the changed demographic characteristics of the PAH patients and a still important diagnostic delay.

Published
2022

22. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure

Author

Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., and Shah, Sanjiv J.

Abstract

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome - a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status - was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P=0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P=0.038). Patients with larger right atrial volum

Published
2022

23. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension:A systematic review and meta-analysis

Author

Hendriks, Paul M., van de Groep, Liza D., Veen, Kevin M., van Thor, Mitch C.J., Meertens, Sabrina, Boersma, Eric, Boomars, Karin A., Post, Marco C., van den Bosch, Annemien E., Hendriks, Paul M., van de Groep, Liza D., Veen, Kevin M., van Thor, Mitch C.J., Meertens, Sabrina, Boersma, Eric, Boomars, Karin A., Post, Marco C., and van den Bosch, Annemien E.

Abstract

Background: Multiple biomarkers have been investigated in the risk stratification of patients with pulmonary arterial hypertension (PAH). This systematic review and meta-analysis is the first to investigate the prognostic value of (NT-pro)BNP in patients with PAH. Methods: A systematic literature search was performed using MEDLINE, Embase, Web of Science, the Cochrane Library and Google scholar to identify studies on the prognostic value of baseline (NT-pro)BNP levels in PAH. Studies reporting hazard ratios (HR) for the endpoints mortality or lung transplant were included. A random effects meta-analysis was performed to calculate the pooled HR of (NT-pro)BNP levels at the time of diagnosis. To account for different transformations applied to (NT-pro)BNP, the HR was calculated for a 2-fold difference of the weighted mean (NT-pro)BNP level of 247 pmol/L, for studies reporting a HR based on a continuous (NT-pro)BNP measurement. Results: Sixteen studies were included, representing 6999 patients (mean age 45.2-65.0 years, 97.3% PAH). Overall, 1460 patients reached the endpoint during a mean follow-up period between 1 and 10 years. Nine studies reported HRs based on cut-off values. The risk of mortality or lung transplant was increased for both elevated NT-proBNP and BNP with a pooled HR based on unadjusted HRs of 2.75 (95%-CI: 1.86-4.07) and 3.87 (95% CI 2.69-5.57) respectively. Six studies reported HRs for (NT-pro)BNP on a continues scale. A 2-fold difference of the weighted mean NT-proBNP resulted in an increased risk of mortality or lung transplant with a pooled HR of 1.17 (95%-CI: 1.03-1.32). Conclusions: Increased levels of (NT-pro)BNP are associated with a significantly increased risk of mortality or lung transplant in PAH patients.

Published
2022

24. Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension

Author

Circulatory Health, Team Medisch, Longziekten, Infection & Immunity, Groen, Karlijn, Huitema, Marloes P., van der Vis, Joanne J., Post, Marco C., Grutters, Jan C., Baughman, Robert P., van Moorsel, Coline H.M., Circulatory Health, Team Medisch, Longziekten, Infection & Immunity, Groen, Karlijn, Huitema, Marloes P., van der Vis, Joanne J., Post, Marco C., Grutters, Jan C., Baughman, Robert P., and van Moorsel, Coline H.M.

Published
2022

25. Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study

Author

Longziekten, Infection & Immunity, Hessels, Josefien, Kroon, Steven, Boerman, Sanne, Nelissen, Rik C, Grutters, Jan C, Snijder, Repke J, Lebrin, Franck, Post, Marco C, Mummery, Christine L, Mager, Johannes-Jurgen, Longziekten, Infection & Immunity, Hessels, Josefien, Kroon, Steven, Boerman, Sanne, Nelissen, Rik C, Grutters, Jan C, Snijder, Repke J, Lebrin, Franck, Post, Marco C, Mummery, Christine L, and Mager, Johannes-Jurgen

Published
2022

26. Predictors of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis

Author

Longziekten, Infection & Immunity, Mathijssen, Harold, Bakker, Annelies L.M., Balt, Jippe C., Akdim, Fatima, van Es, H. Wouter, Veltkamp, Marcel, Grutters, Jan C., Post, Marco C., Longziekten, Infection & Immunity, Mathijssen, Harold, Bakker, Annelies L.M., Balt, Jippe C., Akdim, Fatima, van Es, H. Wouter, Veltkamp, Marcel, Grutters, Jan C., and Post, Marco C.

Published
2022

27. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension

Author

Researchgr. Cardiovasculaire Radiologie, Longziekten, Infection & Immunity, Savale, Laurent, Huitema, Marloes, Shlobin, Oksana, Kouranos, Vasilis, Nathan, Steven D, Nunes, Hiliaro, Gupta, Rohit, Grutters, Jan C, Culver, Daniel A, Post, Marco C, Ouellette, Daniel, Lower, Elyse E, Al-Hakim, Tamara, Wells, Athol U, Humbert, Marc, Baughman, Robert P, Researchgr. Cardiovasculaire Radiologie, Longziekten, Infection & Immunity, Savale, Laurent, Huitema, Marloes, Shlobin, Oksana, Kouranos, Vasilis, Nathan, Steven D, Nunes, Hiliaro, Gupta, Rohit, Grutters, Jan C, Culver, Daniel A, Post, Marco C, Ouellette, Daniel, Lower, Elyse E, Al-Hakim, Tamara, Wells, Athol U, Humbert, Marc, and Baughman, Robert P

Published
2022

28. Value of echocardiography using knowledge-based reconstruction in determining right ventricular volumes in pulmonary sarcoidosis: comparison with cardiac magnetic resonance imaging

Author

Longziekten, Infection & Immunity, Circulatory Health, Team Medisch, Mathijssen, Harold, Huitema, Marloes P, Bakker, Annelies L M, Akdim, Fatima, van Es, Hendrik W, Grutters, Jan C, Post, Marco C, Longziekten, Infection & Immunity, Circulatory Health, Team Medisch, Mathijssen, Harold, Huitema, Marloes P, Bakker, Annelies L M, Akdim, Fatima, van Es, Hendrik W, Grutters, Jan C, and Post, Marco C

Published
2022

29. Type D Personality Associated With Increased Risk for Mortality in Adults With Congenital Heart Disease

Author

Team Medisch, Circulatory Health, Kauw, Dirkjan, Schoormans, Dounya, Sieswerda, Gertjan Tj, Van Melle, Joost P, Vliegen, Hubert W, Van Dijk, Arie P J, Hulsbergen-Zwarts, Mariët S, Post, Marco C, Ansink, Tieneke J, Mulder, Barbara J M, Bouma, Berto J, Schuuring, Mark J, Team Medisch, Circulatory Health, Kauw, Dirkjan, Schoormans, Dounya, Sieswerda, Gertjan Tj, Van Melle, Joost P, Vliegen, Hubert W, Van Dijk, Arie P J, Hulsbergen-Zwarts, Mariët S, Post, Marco C, Ansink, Tieneke J, Mulder, Barbara J M, Bouma, Berto J, and Schuuring, Mark J

Published
2022

30. Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study

Author

Huitema, Marloes P, Post, Marco C, Grutters, Jan C, Wells, Athol U, Kouranos, Vasilis, Shlobin, Oksana A, Nathan, Steven D, Culver, Daniel A, Barney, Joseph, Gupta, Rohit, Carmona, Eva, Alhamad, Esam H, Scholand, Mary B, Wijsenbeek, Marlies, Ganesh, Sivagini, Lower, Elyse E, Engel, Peter J, Baughman, Robert P, Huitema, Marloes P, Post, Marco C, Grutters, Jan C, Wells, Athol U, Kouranos, Vasilis, Shlobin, Oksana A, Nathan, Steven D, Culver, Daniel A, Barney, Joseph, Gupta, Rohit, Carmona, Eva, Alhamad, Esam H, Scholand, Mary B, Wijsenbeek, Marlies, Ganesh, Sivagini, Lower, Elyse E, Engel, Peter J, and Baughman, Robert P

Abstract

INTRODUCTION: Echocardiographic measurement of the right ventricular systolic pressure (RVSP) is commonly used for estimating systolic pulmonary artery pressure (PASP) measured during right heart catheterization (RHC) in patients suspected for pulmonary hypertension (PH). Generally, there seems to be a strong correlation. However, this has been reported as less robust in sarcoidosis. We aim to investigate the correlation between RVSP and RHC measurements using real world data and analyzed factors influencing the relationship between RVSP and PASP in sarcoidosis.METHODS & RESULTS: Data of patients with and without sarcoidosis associated PH who had both a measurable echocardiographic RVSP and invasive PASP were collected from the RESAPH registry, PULSAR study and Cincinnati Sarcoidosis Clinic database (n=173, 60.1% female, mean age 56.0±9.5 years). Among them, 124 had PH confirmed by RHC. There was a strong correlation between RVSP and PASP (r=0.640). This correlation was significant in both male and female, white or non-white, forced vital capacity (FVC) >60%, and presence of fibrosis (p<0.001). However, it was less robust in patients with FVC of 50% or less. RVSP was considered inaccurate if the difference with PASP was > 10mmHg. Inaccurate echocardiographic estimation of the invasive PASP occurred in 50.8%, with overestimation mostly in patients without PH, and underestimation in patients with severe PH. An RVSP>50mmHg was associated with worse survival.CONCLUSIONS: In this real world multicenter cohort of sarcoidosis patients, we found a significant correlation between RVSP as determined by echocardiography and invasive PASP. Over- or underestimation of PASP occurred frequently. Therefore, echocardiographic RVSP measurement alone to screen for PH in sarcoidosis should be used with caution.

Published
2021

32. The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Author

Circulatory Health, Team Medisch, Cardiologie, Hendriks, Paul M, van Thor, Mitch C J, Wapenaar, Monique, Chandoesing, Prewesh, van den Toorn, Leon M, van den Bosch, Annemien E, Post, Marco C, Boomars, Karin A, Circulatory Health, Team Medisch, Cardiologie, Hendriks, Paul M, van Thor, Mitch C J, Wapenaar, Monique, Chandoesing, Prewesh, van den Toorn, Leon M, van den Bosch, Annemien E, Post, Marco C, and Boomars, Karin A

Published
2021

33. Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension

Author

Longziekten, Infection & Immunity, Circulatory Health, Team Medisch, Cardiologie, Mathijssen, Harold, Huitema, Marloes P, Bakker, Annelies L M, Smits, Fokko, Mager, Johannes J, Snijder, Repke J, Grutters, Jan C, Post, Marco C, Longziekten, Infection & Immunity, Circulatory Health, Team Medisch, Cardiologie, Mathijssen, Harold, Huitema, Marloes P, Bakker, Annelies L M, Smits, Fokko, Mager, Johannes J, Snijder, Repke J, Grutters, Jan C, and Post, Marco C

Published
2021

35. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

Author

Circulatory Health, Team Medisch, Cardiologie, Faughnan, Marie E, Mager, Johannes J, Hetts, Steven W, Palda, Valerie A, Lang-Robertson, Kelly, Buscarini, Elisabetta, Deslandres, Erik, Kasthuri, Raj S, Lausman, Andrea, Poetker, David, Ratjen, Felix, Chesnutt, Mark S, Clancy, Marianne, Whitehead, Kevin J, Al-Samkari, Hanny, Chakinala, Murali, Conrad, Miles, Cortes, Daniel, Crocione, Claudia, Darling, Jama, de Gussem, Els, Derksen, Carol, Dupuis-Girod, Sophie, Foy, Patrick, Geisthoff, Urban, Gossage, James R, Hammill, Adrienne, Heimdal, Ketil, Henderson, Katharine, Iyer, Vivek N, Kjeldsen, Anette D, Komiyama, Masaki, Korenblatt, Kevin, McDonald, Jamie, McMahon, Jack, McWilliams, Justin, Meek, Mary E, Mei-Zahav, Meir, Olitsky, Scott, Palmer, Sara, Pantalone, Rose, Piccirillo, Jay F, Plahn, Beth, Porteous, Mary E M, Post, Marco C, Radovanovic, Ivan, Rochon, Paul J, Rodriguez-Lopez, Josanna, Sabba, Carlo, Serra, Marcelo, Shovlin, Claire, Sprecher, Dennis, White, Andrew J, Winship, Ingrid, Zarrabeitia, Roberto, Circulatory Health, Team Medisch, Cardiologie, Faughnan, Marie E, Mager, Johannes J, Hetts, Steven W, Palda, Valerie A, Lang-Robertson, Kelly, Buscarini, Elisabetta, Deslandres, Erik, Kasthuri, Raj S, Lausman, Andrea, Poetker, David, Ratjen, Felix, Chesnutt, Mark S, Clancy, Marianne, Whitehead, Kevin J, Al-Samkari, Hanny, Chakinala, Murali, Conrad, Miles, Cortes, Daniel, Crocione, Claudia, Darling, Jama, de Gussem, Els, Derksen, Carol, Dupuis-Girod, Sophie, Foy, Patrick, Geisthoff, Urban, Gossage, James R, Hammill, Adrienne, Heimdal, Ketil, Henderson, Katharine, Iyer, Vivek N, Kjeldsen, Anette D, Komiyama, Masaki, Korenblatt, Kevin, McDonald, Jamie, McMahon, Jack, McWilliams, Justin, Meek, Mary E, Mei-Zahav, Meir, Olitsky, Scott, Palmer, Sara, Pantalone, Rose, Piccirillo, Jay F, Plahn, Beth, Porteous, Mary E M, Post, Marco C, Radovanovic, Ivan, Rochon, Paul J, Rodriguez-Lopez, Josanna, Sabba, Carlo, Serra, Marcelo, Shovlin, Claire, Sprecher, Dennis, White, Andrew J, Winship, Ingrid, and Zarrabeitia, Roberto

Published
2020

36. Minimally invasive mitral valve surgery: a systematic safety analysis

Author

Circulatory Health, Team Medisch, Onderzoek Molecular Cardiology, Ko, Kinsing, De Kroon, Thom L., Post, Marco C., Kelder, Johannes C., Schut, Karen F., Saouti, Nabil, Van Putte, Bart P., Circulatory Health, Team Medisch, Onderzoek Molecular Cardiology, Ko, Kinsing, De Kroon, Thom L., Post, Marco C., Kelder, Johannes C., Schut, Karen F., Saouti, Nabil, and Van Putte, Bart P.

Published
2020

37. Comparison of Contrast Enhanced Magnetic Resonance Angiography to Computed Tomography in Detecting Pulmonary Arteriovenous Malformations

Author

Circulatory Health, Team Medisch, Van den Heuvel, Daniel A F, Post, Marco C, Koot, Ward, Kelder, Johannes C, Van Es, Hendrik W, Snijder, Repke J, Vos, Jan-Albert, Mager, Johannes J, Circulatory Health, Team Medisch, Van den Heuvel, Daniel A F, Post, Marco C, Koot, Ward, Kelder, Johannes C, Van Es, Hendrik W, Snijder, Repke J, Vos, Jan-Albert, and Mager, Johannes J

Published
2020

38. Genetic Evaluation in a Cohort of 126 Dutch Pulmonary Arterial Hypertension Patients

Author

Genetica, Genetica Klinische Genetica, Circulatory Health, van den Heuvel, Lieke M, Jansen, Samara M A, Alsters, Suzanne I M, Post, Marco C, van der Smagt, Jasper J, Handoko-De Man, Frances S, van Tintelen, J Peter, Gille, Hans, Christiaans, Imke, Vonk Noordegraaf, Anton, Bogaard, HarmJan, Houweling, Arjan C, Genetica, Genetica Klinische Genetica, Circulatory Health, van den Heuvel, Lieke M, Jansen, Samara M A, Alsters, Suzanne I M, Post, Marco C, van der Smagt, Jasper J, Handoko-De Man, Frances S, van Tintelen, J Peter, Gille, Hans, Christiaans, Imke, Vonk Noordegraaf, Anton, Bogaard, HarmJan, and Houweling, Arjan C

Published
2020

41. High burden of drug therapy in adult congenital heart disease : Polypharmacy as marker of morbidity and mortality

Author

Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., Bouma, Berto J., Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., and Bouma, Berto J.

Published
2019

42. Quality of Life Among Patients With Congenital Heart Disease After Valve Replacement

Author

Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, van Melle, Joost P., Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, and van Melle, Joost P.

Published
2019

44. High burden of drug therapy in adult congenital heart disease : Polypharmacy as marker of morbidity and mortality

Author

Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., Bouma, Berto J., Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., and Bouma, Berto J.

Published
2019

45. Quality of Life Among Patients With Congenital Heart Disease After Valve Replacement

Author

Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, van Melle, Joost P., Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, and van Melle, Joost P.

Published
2019

46. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study

Author

Longziekten, Infection & Immunity, Huitema, Marloes P., Bakker, Annelies L.M., Mager, Johannes J., Rensing, Benno J.W.M., Smits, Fokko, Snijder, Repke J., Grutters, Jan C., Post, Marco C., Longziekten, Infection & Immunity, Huitema, Marloes P., Bakker, Annelies L.M., Mager, Johannes J., Rensing, Benno J.W.M., Smits, Fokko, Snijder, Repke J., Grutters, Jan C., and Post, Marco C.

Published
2019

47. High burden of drug therapy in adult congenital heart disease: Polypharmacy as marker of morbidity and mortality

Author

Team Onderzoek, Team Medisch, Circulatory Health, Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., Bouma, Berto J., Team Onderzoek, Team Medisch, Circulatory Health, Woudstra, OI, Meijboom, Folkert J., Kuijpers, Joey M., Post, Marco C., Jongbloed, Monique R.M., Duijnhouwer, Anthonie L., Van Dijk, Arie P.J., Van Melle, Joost P., Konings, Thelma C., Zwinderman, Aeilko H., Mulder, Barbara J.M., and Bouma, Berto J.

Published
2019

48. Quality of Life Among Patients With Congenital Heart Disease After Valve Replacement

Author

Team Medisch, UMC Utrecht, Circulatory Health, Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, van Melle, Joost P., Team Medisch, UMC Utrecht, Circulatory Health, Pragt, Hanna, Pieper, Petronella G., van Slooten, Ymkje J., Freling, Hendrik G., van Dijk, Arie P.J., Sieswerda, Gertjan T.J., Bouma, Berto J., Post, Marco C., Jongbloed, Monique R.M., Willems, Tineke P., Ebels, Tjark, and van Melle, Joost P.

Published
2019

49. RV adaptation to increased afterload in congenital heart disease and pulmonary hypertension

Author

Driessen, Mieke M P, Leiner, Tim, Sieswerda, Gertjan Tj, van Dijk, Arie P J, Post, Marco C, Friedberg, Mark K, Mertens, Luc, Doevendans, Pieter A, Snijder, Repke J, Hulzebos, Erik H, Meijboom, Folkert J, Driessen, Mieke M P, Leiner, Tim, Sieswerda, Gertjan Tj, van Dijk, Arie P J, Post, Marco C, Friedberg, Mark K, Mertens, Luc, Doevendans, Pieter A, Snijder, Repke J, Hulzebos, Erik H, and Meijboom, Folkert J

Published
2018

50. Executive summary of the 12th HHT international scientific conference

Author

Andrejecsk, Jillian W., Hosman, Anna E., Botella, Luisa M., Shovlin, Claire L., Arthur, Helen M., Dupuis-Girod, Sophie, Buscarini, Elisabetta, Hughes, Christopher C.W., Lebrin, Franck, Mummery, Christine L., Post, Marco C., Mager, Johannes J., Andrejecsk, Jillian W., Hosman, Anna E., Botella, Luisa M., Shovlin, Claire L., Arthur, Helen M., Dupuis-Girod, Sophie, Buscarini, Elisabetta, Hughes, Christopher C.W., Lebrin, Franck, Mummery, Christine L., Post, Marco C., and Mager, Johannes J.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results